Itepekimab REGN3500 IL-33 asthma

Itepekimab Patient Guide: How to Get Itepekimab at Low or No Cost

Important Notice: As of March 2026, itepekimab (SAR440340/REGN3500) is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals, Inc. and Sanofi for conditions like chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP). It is not yet FDA-approved, and no commercial patient assistance program exists.[1][2][3] This guide provides general information on accessing itepekimab through clinical trials or potential future programs, along with standard steps for manufacturer assistance programs.

About Itepekimab

Itepekimab is a fully human monoclonal antibody that targets and inhibits interleukin-33 (IL-33), a protein that drives inflammation in respiratory diseases. By blocking IL-33, itepekimab aims to reduce airway inflammation, exacerbations, and symptoms like nasal polyps, congestion, and lung function decline.[1][3][6]

• For COPD: In trials like AERIFY-1 (NCT04701983), itepekimab is tested in former smokers with moderate-to-severe COPD to lower the rate of moderate-or-severe exacerbations, improve FEV1 (lung function), respiratory symptoms, and quality of life via tools like the St. George's Respiratory Questionnaire (SGRQ).[1]
• For CRSwNP: Phase 3 trials (e.g., EFC18418/NCT06834347, EFC18419) evaluate it as add-on therapy to nasal corticosteroids, measuring reductions in polyp size, nasal congestion, and sinus inflammation over 52 weeks.[2][3]

Itepekimab is administered subcutaneously (under the skin), often via prefilled syringe or autoinjector, with studies showing comparable pharmacokinetics.[5] Safety, tolerability, and immunogenicity are ongoing evaluation points.[1]

Since it's investigational, patients access it primarily through clinical trials. Visit ClinicalTrials.gov and search 'itepekimab' for active studies near you.[1][2]

Who Qualifies for Access?

No commercial assistance program is available yet. Eligibility focuses on clinical trial criteria:

• COPD trials: Former smokers, moderate-to-severe COPD, history of exacerbations.[1]
• CRSwNP trials: Adults 18+ with inadequately controlled symptoms despite nasal steroids.[2][3]

Future commercial programs (post-approval) from Regeneron/Sanofi typically target:

• Uninsured or underinsured patients.
• US residents (often).
• Specific medical diagnoses.

Income Eligibility Breakdown

No specific income thresholds are published for itepekimab, as no program exists. Regeneron/Sanofi programs for similar drugs (e.g., Dupixent for COPD) often use 400-800% of the Federal Poverty Level (FPL).[4] Here's a general table for reference (2026 FPL estimates; check HHS.gov for exact figures):

Notes: Thresholds vary; higher incomes may qualify if insured with high copays. Always verify with manufacturer.[4]

Insurance Requirements

For investigational drugs, insurance rarely covers; trials provide free medication. Post-approval:

• Often requires commercial insurance or Medicare Part D (may exclude low-income).
• Government insurance (Medicaid, Medicare low-income subsidy) typically ineligible.
• Uninsured patients prioritized.

Contact Regeneron/Sanofi for expanded access if trials unavailable.

Step-by-Step Application Process

For Clinical Trials (Current Option):

1. Search ClinicalTrials.gov for 'itepekimab' (e.g., NCT04701983, NCT06834347).[1][2]
2. Check eligibility (age, diagnosis, smoking history).
3. Contact trial sites (e.g., UChicago Medicine, Cedars-Sinai).[2][3]
4. Complete screening (4 weeks typical).[2]
5. If enrolled, receive free drug for trial duration (52-76 weeks).[1][2]

For Future Commercial Program (Hypothetical, Based on Similar Programs):

1. Visit Regeneron/Sanofi websites or call 1-888-4-ASSIST (generic example).
2. Download application or apply online.
3. Provide diagnosis from doctor, proof of income (tax returns, paystubs), insurance details.
4. Doctor submits prescription.
5. Approval notification in 1-2 weeks.

Timeline and Delivery

• Trial Enrollment: Screening 4 weeks, treatment 52 weeks, follow-up 20 weeks.[1][2]
• Commercial (Estimated): Processing 5-10 business days; medication shipped to doctor's office or home via specialty pharmacy.
• Refills: Auto-ship or annual renewal.

Alternatives if Denied or Ineligible

• Other Trials: Search for IL-33 inhibitors or COPD/CRSwNP studies.
• Approved Biologics: For COPD, Dupixent (dupilumab) by Regeneron/Sanofi (FDA-approved 2024 for eosinophilic COPD).[4] Access via Dupixent MyWay program.
• General Help: NeedyMeds.org, RxAssist.org, Partnership for Prescription Assistance.
• Biosimilars: None available yet.[4]

Disclaimer

This guide is for informational purposes only and not medical advice. Itepekimab is experimental; discuss risks/benefits with your doctor. Program details may change upon approval. Consult Regeneron (regeneron.com) or Sanofi (sanofi.us) directly. No warranties provided. (Word count: 912)